266 related articles for article (PubMed ID: 26988752)
1. HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.
Lu Y; Wang Y; Zhang M; Liu L; Li F; Zhang J; Ye M; Zhao H; Zhao J; Yan B; Yang A; Zhang R; Li X; Ren X
Oncotarget; 2016 Apr; 7(17):23594-607. PubMed ID: 26988752
[TBL] [Abstract][Full Text] [Related]
2. siRNA delivered by EGFR-specific scFv sensitizes EGFR-TKI-resistant human lung cancer cells.
Lu Y; Liu L; Wang Y; Li F; Zhang J; Ye M; Zhao H; Zhang X; Zhang M; Zhao J; Yan B; Yang A; Feng H; Zhang R; Ren X
Biomaterials; 2016 Jan; 76():196-207. PubMed ID: 26524539
[TBL] [Abstract][Full Text] [Related]
3. miR-367 promotes tumor growth by inhibiting FBXW7 in NSCLC.
Xiao G; Gao X; Sun X; Yang C; Zhang B; Sun R; Huang G; Li X; Liu J; Du N; Liu D; Liang R; Ren H; Qin S
Oncol Rep; 2017 Aug; 38(2):1190-1198. PubMed ID: 28656290
[TBL] [Abstract][Full Text] [Related]
4. TRIM47 overexpression is a poor prognostic factor and contributes to carcinogenesis in non-small cell lung carcinoma.
Han Y; Tian H; Chen P; Lin Q
Oncotarget; 2017 Apr; 8(14):22730-22740. PubMed ID: 28186994
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
[TBL] [Abstract][Full Text] [Related]
6. Silencing of RAD51AP1 suppresses epithelial-mesenchymal transition and metastasis in non-small cell lung cancer.
Wu Y; Wang H; Qiao L; Jin X; Dong H; Wang Y
Thorac Cancer; 2019 Sep; 10(9):1748-1763. PubMed ID: 31317661
[TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
8. Twist may be associated with invasion and metastasis of hypoxic NSCLC cells.
Wei L; Sun JJ; Cui YC; Jiang SL; Wang XW; Lv LY; Xie L; Song XR
Tumour Biol; 2016 Jul; 37(7):9979-87. PubMed ID: 26819207
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.
Ren XL; Xu YM; Bao W; Fu HJ; Wu CG; Zhao Y; Li ZK; Zhang J; Li SQ; Chen WQ; Wang T; Zhang R; Zhang LH; Qian GS; Chen SY; Jia LT; Yang AG
Cancer Lett; 2009 Aug; 281(2):134-43. PubMed ID: 19339104
[TBL] [Abstract][Full Text] [Related]
10. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non‑small cell lung cancer.
Gao J; Qiu X; Xi G; Liu H; Zhang F; Lv T; Song Y
Oncol Rep; 2018 Oct; 40(4):1971-1984. PubMed ID: 30106450
[TBL] [Abstract][Full Text] [Related]
12. LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression.
Zhu T; An S; Choy MT; Zhou J; Wu S; Liu S; Liu B; Yao Z; Zhu X; Wu J; He Z
J Cell Mol Med; 2019 Mar; 23(3):1852-1864. PubMed ID: 30515972
[TBL] [Abstract][Full Text] [Related]
13. MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer.
Yang Y; Liu L; Zhang Y; Guan H; Wu J; Zhu X; Yuan J; Li M
Int J Cancer; 2014 Oct; 135(7):1531-42. PubMed ID: 24550137
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy.
Jiang K; Li J; Yin J; Ma Q; Yan B; Zhang X; Wang L; Wang L; Liu T; Zhang Y; Fan Q; Yang A; Qiu X; Ma B
Biomaterials; 2015 Aug; 59():77-87. PubMed ID: 25956853
[TBL] [Abstract][Full Text] [Related]
15. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer.
Wu X; Liu T; Fang O; Dong W; Zhang F; Leach L; Hu X; Luo Z
Oncotarget; 2016 Jan; 7(3):2417-32. PubMed ID: 26678031
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA CARLo-5 is a negative prognostic factor and exhibits tumor pro-oncogenic activity in non-small cell lung cancer.
Luo J; Tang L; Zhang J; Ni J; Zhang HP; Zhang L; Xu JF; Zheng D
Tumour Biol; 2014 Nov; 35(11):11541-9. PubMed ID: 25129441
[TBL] [Abstract][Full Text] [Related]
18. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells.
Su Z; Yin J; Zhao L; Li R; Liang H; Zhang J; Wang K
World J Surg Oncol; 2014 Dec; 12():367. PubMed ID: 25441176
[TBL] [Abstract][Full Text] [Related]
20. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.
Dong Q; Yu P; Ye L; Zhang J; Wang H; Zou F; Tian J; Kurihara H
Sci Rep; 2019 Apr; 9(1):5692. PubMed ID: 30952931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
